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Introduction Previously reported predictors of mortality have focused on 
mortality during TB treatment. We propose instead to examine TB deaths relative 
to TB treatment. We predict that different characteristics will predict death before 
TB treatment, early in TB treatment and later in TB treatment. 
Methods A retrospective cohort study was performed using data collected on all 
patients reported to the North Carolina TB Control Program in conjunction with 
data obtained from the U.S. National Death Index. Bivariate, multivariate and 
survival analyses were performed to examine relationships between patient 
characteristics and time of death relative to treatment. 
Results Age (adjusted OR=l.04 per year of age, 95%CI 1.03-1.05, HIV/TB co-
infection (adjusted OR=3.44, 95%CI 2.04-5.79) and being an American Indian 
(adjusted OR=4.00, 95%CI 1.47-10.93) were predictors of death before initiation 
of TB treatment. Age (adjusted HR=1.06 each year of age, 95%CI 1.05-1.07), 
black race (adjusted HR=l.35, 95%CI 1.05-1.75), HIV/TB co-infection (adjusted 
HR=1.66, 95%CI 0.99-2.76), history of alcohol abuse (adjusted HR=1.68, 95%CI 
1.17-2.41) and residence in a long-term care facility (adjusted HR=1.70, 95%CI 
1.23-2.34) were predictors of death in the first 8 weeks of treatment. After the 
initial 8 weeks, only age (adjusted HR=1.05 for each year of age, 95%CI 1.04-
1.06) and HIV/TB co-infection (adjusted HR=5.53, 95%CI 3.65-8.44) continued 
to be predictors of mortality. 
Discussion Overall, increasing age and HIV/TB co-infection were predictors of 
death prior to starting TB therapy and during all stages of TB therapy. Additional 
TB patient characteristics also existed that predict death specifically before 
treatment or in the early weeks of treatment. 
INTRODUCTION 
Burden of Disease 
Tuberculosis (TB) is a contagious but curable disease that continues to affect 
millions of people worldwide. Caused by Mycobacterium tuberculosis, TB can be 
spread to others when those with active pulmonary TB cough, propelling 
respiratory droplets laden with TB bacilli into the air. It is estimated that there 
were 8.3 million new TB cases worldwide in 2000, with an annual case rate 
increase of 1.8% each year between 1997 and 2000[1]. Additionally, despite 
directly observed treatment, short-course (DOTS) strategy, TB related mortality 
figures remain unacceptably high around the world. 
Although the Americas do not carry the burden of disease that other regions of the 
world carry, 2004 TB incidence rates range from 5.5 per 100,000 people in 
Canada to 188.0 per 100,000 people in Peru[2]. In the United States, 14,511 new 
cases (4.9 cases per 100,000 people) of confmned TB in the United States were 
documented in 2004. Though this is the lowest case rate to be reported since 
1953, the 3.3% decline from 2003 is only the second smallest yearly decline since 
1993[3]. The U.S. also saw 802 deaths (0.3 deaths per 100,000 people) directly 
attributed to TB in 2002, representing a 5.0% increase from the previous year and 
the first increase in U.S. TB deaths sincel989[4]. Data on the 2003 and 2004 TB 
deaths are not currently available 
Predictors of Mortality 
TB associated mortality may occur prior to initiation of TB therapy, during TB 
therapy or subsequent to TB treatment completion. However, most studies that 
have examined predictors of TB-associated death have focused only on death 
during TB treatment. Reported predictors of mortality during TB treatment 
include medical co-morbidities[ 5-l 0], previous TB treatment[?, 11 ], HIV 1TB co-
infection[10, 12-14], low weight[9, 15] and alcoholism[ll, 16]. Less frequently 
reported risk factors include home1essness[8], significant weight loss[ll] and 
multidrug resistance[13]. Older age has been shown to be a predictor ofTB death 
in some community-based treatment settings [5, 7, 16, 17], but not in others[8, 
15, 18]. In general, the studies discussed thus far focus on risk factors that predict 
death in patients undergoing TB treatment, with little distinction between 
characteristics associated with death early in treatment versus later in the 
treatment period. However, TB associated deaths occur at many points in the 
course of TB treatment and it may be possible to clarifY some of the variation by 
examining mortality risk factors relative to time ofTB treatment. 
A handful of studies have reported the frequency of death prior to TB 
treatment[ll, 17, 18] (Appendix A). Additionally, Farah et al. reported that the 
median age of those who died prior to TB treatment was 71 years of age [17]. 
Walpola et al. presented a limited case series of 25 patients who died prior to 
treatment; 28% of these patients died prior to or within one day of presentation 
while the other 72% presented more than one day before death but were not 
diagnosed with TB until after death [18]. 
After these initial deaths prior to TB treatment, death can be viewed as occurring 
in two phases during TB therapy: the initial weeks of TB therapy and the later 
weeks of treatment. The early treatment time period may include hospital 
admission and represent a time of high acuity of illness. A study by Sacks et al. 
reported that 32% of hospitalized TB patients died within the first 7 days of 
admission; 50% of admitted TB patients died by day 19 ofhospitalization[9]. On 
the other hand, the later treatment time period (representing those who died after 8 
weeks of treatment) may involve toxicity to treatment medications, treatment 
failure or medical co-morbidities. The identification of risk factors associated 
with death early in treatment compared to factors associated with death later in 
treatment may prove useful in the development of specific strategies to prevent 
TB mortality. Likewise, the identification of predictors of death before initiation 
of TB treatment may allow for targeted public health efforts that will decrease TB 
related death. Lastly, continued study of death during TB treatment is important to 
confirm previously reported risk factors, as well as identify factors that have not 
been studied thus far. 
This study sets out to explore TB patient characteristics associated with death in 
the state of North Carolina, which is located in the southeastern United States. 
The southeastern United States has the highest percentage of households with 
incomes below the federal poverty level of any region in the country[l9], and is 
different from the urban populations usually studied in the United States as it 
comprises a predominantly rural population whose source of health care is 
geographically scattered. Additionally, the 2000 United States National Census 
revealed that the Hispanic/Latino population in North Carolina grew by 379% 
between 1990 and 2000, the largest change in proportion of any state in the 
U.S.[20]. Given that foreign born individuals make up an increasing proportion 
of the TB cases in the United States[21 ], further analysis of TB risk factors in 
North Carolina may provide useful clues for public health and individual health 
care providers regarding the future of TB in America. Hence, the study of TB in 
North Carolina offers a perspective on TB that is unique from past U.S. studies in 
setting while also providing data on a population that is in fact similar to other 
non-urban U.S. populations. 
Study Aims and Hypotheses 
The primary goals of this study were to determine the demographic and 
behavioral risk factors associated with mortality among patients diagnosed with 
TB in North Carolina during the ten year period, 1993 to 2003. TB-associated 
mortality was evaluated relative to treatment, using the following subgroups: (I) 
death prior to initiating TB treatment, including those who were already dead at 
TB diagnosis (2) death early in TB treatment and (3) death later in TB treatment. 
We hypothesize that we will be able to identify patient-specific characteristics 
that are significantly associated with the different times of death. 
Additional specific hypotheses that we postulated include: environmental factors 
would be identified that were significantly associated with overall mortality; 
patients under age 5 and over age 65 would be more likely to die early in TB 
treatment than patients age 5-64; patients with history of homelessness and/or 
alcohol abuse would have higher rates of death prior to initiation of TB treatment 
than those without history of homelessness or alcohol abuse; patients who were 
homeless will have higher mortality rates later in TB treatment than TB patients 
who were not homeless. 
METHODS 
Study design 
We performed a retrospective cohort study comparing the impact of various 
patient characteristics on death in TB patients who were reported to the North 
Carolina State TB Control Program between January 01, 1993 and December 31, 
2003. 
Institution Approval 
The project was performed subsequent to approval by the Institutional Review 
Boards (IRBs) of Duke University Health System, the University of North 
Carolina-Chapel Hill's School of Public Health, and the North Carolina 
Department of Health and Human Services' Division of Public Health, 
respectively. Each IRB granted a waiver of consent and HlPAA authorization, 
and we sufficiently met all requirements for data storage and protection of 
confidentiality. Additionally, approval to query the U.S. National Death Index 
(NDI) was granted by the National Center for Health Statistics. 
Sample 
Our cohort study includes data that are routinely collected on adult and pediatric 
patients diagnosed with active TB via the Centers of Disease Control and 
Prevention (CDC) data collection instrument, the Report of Verified Case of TB 
(RVCT). This instrument captures all TB cases within the state ofNorth Carolina, 
including cases diagnosed after death via autopsy or culture specimens that grow 
M tuberculosis after the patient has died, and cases that are based on a clinical 
diagnosis. This data is entered into a CDC database, the Tuberculosis Information 
Management System (TIMS), and downloaded into the North Carolina TB 
Control Program's Microsoft Access™ database. The North Carolina TB Control 
Program's data set was used in conjunction with information obtained from the 
NDI. The NDI is a national mortality database that has been shown to be a 
reliable source of U.S. mortality data for medical and health research[22-24]. The 
national database contains identifYing data from state-mandated death certificates 
from all fifty states, New York City, the District of Colombia, Puerto Rico and the 
Virgin Islands. 
NDI Query Methods 
Subjects who died prior to or during TB therapy were identified in the RVCT 
records. The NDI was used to confirm time of death for these subjects, as well as 
capture any deaths that were not identified by RVCT records, by sending the 
identifYing data of all subjects obtained from the RVCT to the NDI to query for 
linked records. Data sent for linking included subjects' Social Security number 
(SSN), full name, date of birth (DOB), race, gender and last known state of 
residence, as entered in the North Carolina TB Control Program's Microsoft 
Access™ database. 
Once the results of the NDI query were received, the records that correctly linked 
subjects found in the North Carolina TB Control Program's Access database with 
those in the NDI database were separated from the inaccurate or false record 
matches. To do so, specific link criteria (listed in Appendix B) were applied. 
Records that did not fulfill any of the above requirements were discarded as 
inaccurate or false matches. The dates of death obtained from the correctly linked 
records were used in analyses of death relative to TB treatment. 
Inclusion/Exclusion Criteria 
All patients reported to the North Carolina TB Control Program were included in 
the analyses. At the time of this study, death records up to December 31, 2003 
were available from the NDI for all patients. All deaths that occurred by 
December 31,2003 were included in the analyses. 
Outcome Groups 
Analyses focused on three outcome subgroups derived from timing of death. The 
subgroup referred to as 'death prior to initiation of treatment' comprises all 
reported TB patients who were diagnosed with TB but died before any TB 
therapy was started; this subgroup includes patients who were diagnosed at 
autopsy. The subgroup called 'death early in TB treatment' refers to all TB 
patients who began TB therapy with the North Carolina TB Control Program but 
died within the initial eight weeks of treatment and hence prior to completion of 
treatment. The subgroup referred to as 'death later in TB treatment' comprises all 
TB patients who initiated TB therapy, survived past eight weeks but died prior to 
completion ofTB treatment. 
Exposure Variables 
The elements reported in the RVCT were used to examine which patient 
characteristics predicted death in the different subgroups. The demographic, 
clinical and social (such as homelessness or excess alcohol use) characteristics 
were based on either documented patient medical history or by patient self-report, 
as recorded by public health nurses via the RVCT. The variables used in our 
analyses are listed in Appendix C. 
With regard to the race variable, in January 2003 the RVCT changed how it 
categorized patients' race. Prior to 2003, patients were characterized as one of 
four races: White, Black, American Indian or Alaskan Native, and Asian or 
Pacific Islander. The 2003 RVCT separated 'Asian or Pacific Islander' into two 
distinct categories, resulting in a total of five possible race choices. Patients are 
now characterized as White, Black or African American, American Indian or 
Alaskan Native, Asian, or Native Hawaiian or Other Pacific Islander. For the data 
analysis of this study, the patients who were separated into Asian and Hawaiian or 
Other Pacific Islander categories by the 2003 RVCT were collapsed into one 
Asian-Pacific Islander category. 
Statistical Analysis 
The primary outcome of this study is time to death. Statistical analyses were 
performed with Stata 8.1 (Stata Corporation, College Station, TX) and SAS, 
version 9.1 (SAS Institute, Inc., Cary, NC) software packages. Bivariate analysis 
was performed to examine the relationship between various patient characteristics 
and the time of death relative to treatment. Differences in proportions were 
assessed using the chi-square test or Fisher's exact test, as appropriate. 
Differences in survival among groups with different demographic and risk 
profiles were examined using the Kaplan-Meier method with survival functions 
compared with the log-rank test. 
Logistic regression modeling and Cox proportional hazards regression modeling 
were used to examine the independent effects of multiple factors on time of death. 
With regard to variables in which values were labeled as "positive", "negative" or 
"unknown", such as HIV status, those with "unknown" values were assigned to 
the "negative" category. Recognizing that this may result in the misclassification 
of an unknown number of subjects, multiple imputation via the Markov chain 
Monte Carlo method [25-27] was used to determine the potential effect of missing 
data on the multivariate models. To do so, SAS 9.1 's PROCMI command was 
used to generate 10 imputed datasets. The PROC MIANAL YZE command was 
then used to combine odds ratio or hazards ratio estimates from regression models 
performed on each of these datasets and generate confidence intervals that 
incorporated the missing-data uncertainty; these imputed point estimates were 
compared to the estimates obtained from our logistic and Cox proportional 
hazards regression models. 
Odds ratios, hazards ratios and 95% confidence intervals were calculated where 
appropriate. Age was treated as a categorical variable, using TIMS-specified age 
groups, in the univariate analysis and as a continuous variable in the multivariate 
analyses. For all statistical tests, a p-value ::;:0.05 (two-tailed) was considered 
significant. 
Power Calculation 
Statistical power of the overall sample was approximated usmg a survival 
outcomes calculator found at the following website: 
h!lg:! /vvvrw.ihsuh.edu/Rese2rch/Centers/CCT /iavmnarc/SSP l /SSP 1 v4ccthtm. We 
based our calculation on an estimated sample size of 5000 patients, representing 
our entire study cohort. We assumed 10% exposure prevalence, with exposure 
referring to the presence of one of the clinical or social variables under study, 
such as HIV status; this exposure prevalence is based on an initial query of our 
database. We will use Variable X to refer to one of those variables in our 
description. Assuming that I 0% of the population has a positive history of 
Variable X, the control survival rate, or rate of survival in those without a history 
of Variable X, was set at 80% and the relative risk of dying in the exposed versus 
the control group was conservatively estimated to be 1.5. Using these figures, at a 
= 0.05, the probability that our sample will be able to detect a true difference in 
overall survival, based on Variable X, is 89.8%. This power increases with 
decreased control survival or increased exposure prevalence. 
RESULTS 
Overall Patient Characteristics 
A total of 5,311 patients were captured by the North Carolina TB Control 
Program between 1993 and 2003, and their overall demographic and social 
characteristics are shown in Table 1. 
30.4% (n = 1,614) of the study population fell between 25 and 44 years old while 
another 30.6% (n=1,624) were at least 65 years old. Over one-third (34.5%, n= 
1,834) of the cohort was female. 18.1% (n = 4,348) of patients were born outside 
of the United States. 
10.3% (n = 549) of the study population was HIV-positive, though 39.7% (n = 
2,1 09) of patients were of unknown HIV status because the patients either refused 
the test, were not offered the test or the result of the test was not recorded. 2.0% 
(n = 106) of the study population was incarcerated at the time of the TB diagnosis, 
and 4.7% (n = 250) were living in a long-term care facility when diagnosed. 7.1% 
(n = 377) reported being homeless within the past year. 1.8% (n = 96) were 
injection drug users, and 9.1% (n = 483) used non-injection drugs. Excess alcohol 
use within the past year was reported in over one-fifth (21.6%, n = 1,147) of the 
study population. 
Little drug resistance was seen in the study cohort, as only 1.7% (n = 90) of 
patients' isolates' susceptibility testing showed mono-resistance to INH; 1.4% (n 
= 76) showed resistance to both INH and at least one other drug, excluding RIF 
resistance. 0.4% (n = 21) of subjects had evidence of both INH and RIF 
resistance. Three-quarters (n = 3,982) of the cohort had pulmonary TB, and an 
additional4.6% (n = 243) had both pulmonary and extra pulmonary disease. 
Additional clinical characteristics of those with pulmonary TB are listed in Table 
2. 28.6% (n = 1,208) of pulmonary TB patients were reported as "cavitary" on 
chest radiograph and almost half ( 49.8%, n = 2,1 03) had a positive sputum smear. 
The majority of pulmonary TB patients in the study cohort (70.0%, n = 2,953) 
were sputum culture positive forM tuberculosis. 
Patient Mortality 
Of the total study cohort, 3.4% (n=18l) died before initiation ofTB treatment (see 
Table 3). The remaining patients were started on antituberculous therapy but a 
total ofl0.8% (n=540) died before completion of therapy. 5.9% (n= 305) of those 
who started treatment died within the first eight weeks of treatment, while 4.9% 
(n=235) of those who survived the initial eight weeks of TB treatment 
subsequently died prior to treatment completion. 86.4% ( 4,590/5,311) of the 
original patients initiated and completed TB therapy. 
Mortality Prior to Initiation of Treatment 
Bivariate analyses showed that age, race, ethnicity, country of origin, HIV status, 
long-term care facility residence, IDU, non-IDU and excess alcohol use were all 
significantly associated with death prior to starting antituberculous treatment 
(Tables 4-6). 
Once multivariate analyses were performed, increasing age, IDVITB co-infection 
and American Indian race were significant predictors of death in the time period 
prior to initiation of TB therapy (Table 7). For each decade increase in age, the 
mortality odds before TB treatment increased by 0.48 (age as a continuous 
variable, adjusted OR=l.48, 95%CI 1.34-1.63). Those with IDVITB co-infection 
had 3.44 times the odds of mortality prior to TB treatment (adjusted OR=3 .44, 
05%CI 2.04-5.79) and compared to their white counterparts, those of American 
Indian or Alaskan Native race had 4.00 times the odds of dying before they start 
TB treatment (adjusted OR=4.0, 95%CI 1.47-10.93). 
Gender, black race, Asian race, Hispanic ethnicity, prior TB infection, history of 
homelessness, history of excess alcohol use, history of injection drug use, history 
of non-injection drug use, incarceration at diagnosis and residency in a long-term 
care facility at diagnosis did not significantly predict death in the time period 
prior to TB treatment initiation in our model . Of note, the subgroups representing 
mortality before TB treatment based on Asian race, Hispanic ethnicity, history of 
previous TB, history of homelessness, history of injection drug use, history of 
non-injection drug use, and incarceration at diagnosis each comprised less than 20 
(n < 20) patients, respectively. Hence, results must be interpreted with caution. 
The multiple imputation procedure produced odds ratio estimates (see Table 9) of 
variables predicting death before treatment initiation similar to the estimates 
reported above. 
Mortality in the Early Weeks of Treatment 
Bivariate analyses of patients who started TB therapy but died within the frrst 
eight weeks of treatment revealed that age, race, ethnicity, country of origin, HIV 
status, residency in a long term care facility, incarceration at time of diagnosis, 
homelessness, and non-IDU were significantly associated with death in these 
early weeks of treatment (Tables 4-6). 
After Cox proportional hazards modeling, significant predictors of death in the 
initial eight weeks ofTB therapy were increasing age, being a U.S.-bom person of 
black race, history of excess alcohol use within the previous 12 months, and 
residency in a long-term care facility at the time of diagnosis (Table 8). 
The mortality risk in the early weeks of treatment increased by 0.79 for each 
decade increase in age (age as a continuous variable, adjusted HR=1.79, 95%CI 
1.63-1.97). Persons of black race had 1.35 times the risk of mortality in the early 
weeks when compared to persons of white race (adjusted HR=1.35, 95%CI 1.05-
1.75), subjects with a history of excess alcohol use had 1.68 times the risk of 
mortality in the early weeks(adjusted HR=1.68, 95%CI 1.17-2.41), and residents 
of long term care facilities had 1. 70 times the mortality risk in the early weeks of 
treatment (adjusted HR=l.70, 95%CI 1.23-2.34). HIV/TB co-infection 
approaches statistical significance as a predictor of death within the frrst 8 weeks 
ofTB therapy. Those who died in the early weeks ofTB treatment had 1.66 times 
the risk of mortality when compared to those who did not have HIV/TB co-
infection (adjusted HR=1.66, 95%CI 0.99-2.76). 
Variables that were not significant predictors of death in the multivariate model 
were gender, Asian race, American Indian race, Hispanic ethnicity, prior TB 
infection, history of homelessness, history of injection drug use, history of non-
injection drug use and incarceration at diagnosis. Of note, the following 
subgroups had less than 20 (n < 20) patients who died early in treatment and thus 
results must be interpreted with caution: Asian race, American Indian race, 
Hispanic ethnicity, history of homelessness, history of injection drug use, history 
of non-injection drug use and incarceration at diagnosis. 
The multiple imputation procedure produced hazards ratio estimates of the 
variables that predicted death early in TB treatment (see Table 9) similar to the 
estimates reported above. 
Mortality in the Later Weeks of Treatment 
Age, race, ethnicity, country of origin, gender, HIV status, history of previous TB, 
TB disease site, residence in a long-term care facility, IDU and excess alcohol use 
were all associated with death later in treatment in bivariate analyses of patients 
who were started on TB therapy but who subsequently died after eight weeks of 
treatment (see Tables 4-6). 
Once Cox proportional hazards modeling was performed, only increasing age and 
HIV!fB co-infection predicted death in the later weeks ofTB therapy (see Table 
8). With each decade increase in age, there was 0.63 times the mortality risk in the 
later weeks of treatment (age as a continuous variable, adjusted HR=l.63, 95%CI 
1.48-1.79). HIV!TB co-infected subjects had 5.53 times the risk of mortality in 
the later weeks of treatment (adjusted HR=5.53, 95%CI 3.65-8.44). 
The variables that did not significantly predict death in the later weeks in the 
multivariate model were black race, Asian race, American Indian race, Hispanic 
ethnicity, prior TB infection, history of homelessness, history of excess alcohol 
use, history of injection drug use, history of non-injection drug use, residency in a 
long term care facility at time of diagnosis and incarceration at diagnosis. The 
subgroups representing death later in treatment by Asian race, American Indian 
race, Hispanic ethnicity, history ofhomelessness, history of injection drug use and 
incarceration at diagnosis each had less than 20 (n < 20) patients, respectively. 
Therefore these results must be interpreted with caution. 
The multiple imputation procedure produced hazards ratio estimates of 
characteristics that predicted death in the later weeks of TB treatment (see Table 
9) similar to the hazard ratio estimates reported above. 
DISCUSSION 
This analysis goes beyond previous TB-mortality studies by examining mortality 
risk factors relative to TB treatment, and examining the various patient 
characteristics which may differentially affect dying prior to initiation of 
treatment, dying early in treatment, and dying later in treatment. We found that 
increasing age and HIV ffB co-infection are predictors of TB mortality at nearly 
all points oftime relative to treatment. In addition, we found that being a person 
of American Indian race specifically predicts death prior to TB treatment while 
being a person of black race, being a resident of a long-term care facility or 
having a history of excess alcohol use specifically predict death in the first eight 
weeks of treatment. Other than increasing age and HIV!TB co-infection, no other 
variables specifically predicted death in the later weeks of treatment. 
With regard to the specific hypotheses postulated by this project, it was 
hypothesized that environmental factors, or factors relating to the social 
surroundings of the TB patient, would be significantly associated with overall 
mortality; rates of TB and overall death are significantly higher in drug and 
alcohol abusers than the general population[28]. Though we found that residents 
of long-term care facilities and those with excess alcohol use experienced 
significantly higher mortality in the early weeks of treatment, these associations 
were not observed in the time period before treatment initiation or beyond the first 
few weeks of treatment. There was no association between any specific social 
characteristic, such as illicit drug use, alcohol use or homelessness, and overall 
mortality in our study cohort. However, it is worth nothing that HIV/TB co-
infection has been treated thus far as a clinical characteristic in this study. The 
argument could be made though, that as HIV continues to disproportionately 
affect young, impoverished and frequently minority adults, HIV /TB co-infection 
is indeed as much related to the social enviromnent of a patient as it is related to 
the clinical picture of the patient. Harries et a!. suggests that the social, cultural 
and economic issues of poverty, sexual activity, illiteracy and stigma affect the 
access to care, diagnosis and delivery of care to HIV /TB co-infected patients[28]. 
If thus treated as a social characteristic of a patient, then our results support 
HIV /TB co-infection as an enviromnental factor that is significantly associated 
with overall mortality in TB patients. 
Another postulated hypothesis was that patients under age 5 and over age 65 
would be more likely to die early in treatment than patients aged 5-64. Indeed, we 
found that increasing age is significantly associated with increased mortality in 
every phase studied. The overall decreased survival associated with increasing 
age that we observed in this cohort confirms previously cited studies that also 
associated increased age with increased mortality [5-7, 16, 17]. This age group's 
association with increased TB mortality, both in the early treatment weeks and 
overall, may be due to TB disease itself, due to confounding medical co-
morbidities that we were unable to explore in our database, or simply due to the 
overall frailty of old age. Regarding patients under age 5, only one patient (0.9%) 
in this age group died prior to or during TB treatment. Though the single child 
who died within this age group in fact died within the first 8 weeks ofTB therapy, 
no association could be found between young age and decreased survival in the 
early part of treatment as there were too few cases to draw conclusions. Thus, we 
reject the hypothesis that patients under age 5 are more likely to die early in 
treatment but accept the hypothesis that older patients are more likely to die in the 
fust few weeks of treatment. 
It was also postulated that patients with a history of homelessness and/or alcohol 
abuse would have higher rates of death prior to starting TB therapy than those 
without history of homelessness or alcohol abuse. We were not able to show a 
significant association between these factors and increased mortality before 
initiation of treatment in our multivariate analyses and reject the postulated 
hypothesis. However, it is notable that these subgroups were small and hence 
these negative results may be due to underpowered subgroup analyses. 
Similarly, we hypothesized that homeless TB patients would have decreased 
survival in the later weeks of TB treatment, under the assumption that such 
patients would be lost to follow-up or would not be able to comply with the 
lengthy and complicated treatment regimen. According to Lobato et a!., only 26% 
of homeless patients completed INH treatment for latent TB infection[29]. Given 
this low treatment completion rate, we predicted that patients with history of 
homelessness would have increased mortality in the late weeks of treatment. 
However, we did not detect a significant difference in mortality based on 
homelessness in those who died late in TB treatment in our cohort. This may be 
because the number of homeless patients who died late in treatment was small 
(n=ll ), making it difficult to draw conclusions. Future studies with adequate 
statistical power should reexamine the hypothesis that patients with history of 
homelessness will have increased mortality in the later weeks of treatment. 
As we examine the results of our analyses, certain themes emerge. One recurring 
motif is increased mortality in social groups traditionally disenfranchised from 
U.S. society: the elderly, the physically and mentally frail who occupy our long-
term care facilities, American Indians, blacks, alcoholics and the HIV-infected. 
The increased TB death in our senior citizens may be due to factors already 
discussed previously, or they may be partially attributed to the social isolation that 
faces many of the elderly in America. Studies on the health effects of social 
isolation on the elderly have reported that pre-stroke social isolation predicted 
poorer post-stroke outcomes like myocardial infarct[30] and that advanced age 
and living alone are associated with heat-wave related death[31]. Elderly who live 
alone may experience delayed TB detection and diagnoses and hence increased 
disease severity by the time of diagnosis and treatment. In addition, though we 
were unable to fmd an association between TB mortality and the youngest 
patients in our study cohort, the low mortality observed in this age group could be 
because pediatric TB cases often go undiagnosed. Patients under age 5 may not be 
captured by public health surveillance, as TB in children can often present with 
nonspecific symptoms [32]. Additionally, according to Feja et a!., a 
disproportionate proportion of pediatric TB cases are found in Hispanic, non-
Hispanic Black and foreign-born children. These populations may be beyond the 
reach of the U.S. health system either from lack of access or fear of immigration 
services, and thus go undetected by standard TB surveillance. It is unclear if the 
lack of deaths in our young TB patients may be confounded by these complex 
social issues or in fact simply due to a very low mortality rate within this age 
group. 
Race also plays an interesting role as a predictor of death in TB patients, as our 
analyses showed that being an American Indian or Alaskan native predicted 
decreased survival prior to initiation of treatment while being black predicted 
decreased survival in the early weeks of treatment. American Indians and Alaskan 
natives, as a racial minority, have been significantly disempowered by U.S. 
society. Those who live on Indian reservations live amidst poverty, low education, 
high rates of drug abuse and overall poor health outcomes; a report from the 
Indian Health Service showed that 31.6% of Indians residing in current 
reservations were below the federal poverty level and only 8.9% were college 
graduates, compared to 13.1% and 20.3%, respectively, of the overall U.S. 
population [33]. Given such social conditions, it is likely that Native American 
TB patients may not have the access to health care that would lead to prompt TB 
diagnoses, and hence may die before they are even diagnosed. Additionally, 
bureaucratic barriers between county-based public health and reservation-based 
health care delay TB diagnosis and contribute to the association of American 
Indian race with mortality before TB treatment. To study this association further, 
we intend to geographically map the cases of Native American TB death in North 
Carolina to assess for clustering within specific counties and to try to correlate 
these clusters with proximity to county public health services. 
Blacks in America are another traditionally disenfranchised population and 
reports of disparities between blacks and whites in specific health outcomes are 
becoming increasingly commonplace. In 2004, blacks had a disproportionately 
increased TB case rate (11.1 per 100,000 people) when compared to whites (1.3 
per 100,000 people) and the overall U.S. case rate (4.9 per 100,000) [3]. However, 
the same report also states that the similar percentages of blacks and whites 
receive DOT and complete treatment on time. Our results support this finding, as 
being black was not associated with decreased survival in the later weeks of 
treatment, when death is presumed to result from treatment failure or co-morbid 
conditions. The increased mortality in our black TB patients in the early weeks of 
TB treatment is troubling however. These patients may be at increased risk of 
death due to many reasons, such as delayed diagnoses, misdiagnoses, or the 
inability to access health care. In addition, a study of the southeastern region of 
the U.S. showed that black TB patients in this region were more likely than their 
white counterparts to have risk factors associated with lower socioeconomic 
status, such as increased rates of excess alcohol use, drug use, incarceration and 
IDV/TB co-infection[19], which may complicate TB diagnosis and treatment in 
these patients. A CDC study is currently underway to examine barriers to health-
seeking and treatment compliance in blacks with TB, barriers to TB guideline 
adherence by providers who treat blacks with TB, interventions to overcome these 
barriers and improve collaborations among TB programs, providers and 
organizations serving black communities in the U.S.[3]. 
Though the trend of increased mortality in these disempowered social groups is 
troubling, it also reveals one strong point of this study. In using the North 
Carolina TB Control Program's RVCT-collected data, comprised of all TB 
patients mandatorily reported to a state TB control program over an extended 
period of time, this study population is likely comparable to the TB populations in 
other states within the U.S. There is less concern for the effects of selection bias 
introduced by a study cohort who, for instance, were enrolled in a specific clinical 
trial, were actively recruited to join a study or even patients listed in a tumor 
registry, who had enough access to health care to be evaluated for a malignancy. 
Hence, our results may be more generalizable to other TB populations than 
studies that derive their study populations in another manner or which specifically 
focus on population subgroups, such as hospitalized, pediatric, homeless or 
incarcerated TB patients. 
Although the RVCT-collected data provides a broadly representative group for 
study, there are flaws inherent with the database. One weakness of the database is 
the proportion of missing data, particularly regarding social risk factors. For 
instance, approximately 14-15% of the patients within our study cohort had 
unknown substance abuse behaviors. Though plausible that social factors such as 
homeless status could not be collected on individuals who died prior to starting 
treatment, especially if diagnoses occurred at autopsy or in other situations after 
death, the high proportion of social information not collected via the RVCT could 
also be due to lack of documentation in the medical record, patient failure to self-
report, differences in the data collected because of a lack of standard defmitions, 
and differences in interpretation of medical records and patient report by health 
professionals across the state, over a ten year time period. Failure of the health 
care provider to query about these specific social history factors may also 
contribute to the missing data. For example, a study by Stout et a!. reports that 
despite recommended universal IDV testing for patients with TB, only 67% of TB 
patients from 1993 to 1999 were offered IDV testing in North Carolina [34]. We 
addressed our concern about the proportion of missing data with the use of 
multiple imputations of our multivariate models to determine the potential effect 
of the missing data on our results. We found that imputations of the missing data 
did not affect significant associations between certain patient characteristics and 
mortality relative to TB treatment. 
Additional concerns include the small sample sizes of our risk factor subgroups 
and the inability to detect other potentially important risk factors via current CDC 
TB surveillance techniques. The small sample sizes of certain exposure groups, 
for instance the subgroup homelessness in those who died early in treatment (n = 
111235; 3.1 %), diminishes the statistical power to detect a true difference in these 
exposure groups, and may preclude defmitive conclusions. Unfortunately, these 
small sample sizes dominate several other exposure groups of interest as well, 
such as injection and non-injection drug use, and incarceration. And though the 
RVCT-collected data contains extensive information on patients' TB disease, like 
drug susceptibility and sputum culture conversion, the TB surveillance does not 
include data related to patients' socioeconomic status (SES), such as income or 
SES proxies such as education level. The RVCT also does not collect data on TB 
patients' co-morbid conditions, such as malignancy or malnourishment, which 
may contribute to mortality in these patients. 
With regard to future endeavors, we have analyzed risk factors for mortality 
before TB treatment, during the first weeks and then the later weeks of TB 
treatment thus far. We also intend to explore mortality after TB treatment 
completion. We observed that 17.3% of our study cohort who survived TB 
treatment subsequently died by December 31, 2003. This number was larger than 
expected, and may be an important group to study, as becoming ill with active TB 
may be a harbinger of declining health status. While TB may be diagnosed and 
cured, people with a history of TB may have a higher mortality rate following 
completion of TB treatment compared to a demographically matched population. 
Furthermore, known sequelae of TB disease, such as bronchiectasis with recurrent 
bacterial infection, may contribute to a decreased life span in patients who 
complete TB treatment. Little research has been done to identity those who die 
shortly after completion ofTB treatment; no studies could be found by the author. 
Future studies directed at mortality in patients who completed TB treatment may 
provide insight into predictors of death in this population. 
In summary, our study used a new paradigm in which to examine TB mortality by 
examining death relative to TB treatment. We found that age and HIV!TB co-
infection are associated with increased mortality both before and during TB 
treatment, and also found specific risk factors associated with dying prior to 
starting treatment and dying in the early weeks of TB treatment. We hope that 
these specific factors can be used to generate targeted public health efforts that 
will decrease TB related mortality. 
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Appendix A: Studies that examined deaths prior to initiation ofTB treatment, 
and their respective fmdings. 
Study Country Overall Total TB Death Prior to TB ·. 
Study Size Deaths Treatment 
Farah eta!. Norway N=655 n=58 • 32.8% of total TB (2005) deaths 
• 2.9% of total TB cases 
• 0.6% ofTB cases were 
diagnosed at autopsy; 
• median age of those 
who died before TB 
treatment was 71 years 
Garcia- Mexico N=454 n=34 • 5.9% of total TB deaths 
Garcia et al. • 0.4% of total TB cases (2002) 
Walpolaet Australia N= 1083 n=87 • 37.9% of total TB 
a!. (2003) deaths 
• 3.0% of total TB cases 
• 2.3% ofTB cases were 
diagnosed at autopsy 
Appendix B. Link criteria applied to the results of the NDI query to distinguish 
correctly linked NDI/RVCT records from false or inaccurate links. 
If the patient's SSN is available: 
1) SSN, first name, last name, middle initial, DOB, gender, race and state of 
residency 
2) first name, last name, middle initial, DOB, gender, race and SSN with either 
one incorrect digit or 2 consecutive incorrect digits 
3) SSN, DOB, gender and race 
4) SSN, first name, last name, day and/or month of birth and year of birth+/- 3 
years 
5) SSN, last name, day of birth, month of birth and year of birth +/-10 years. 
If the SSN was not available and the subject's last name was not among the 
two hundred fifty most frequent U.S. last names/ then the following criteria 
were used: 
1) first name, last name, middle initial, DOB, state of residence and gender 
2) first name, last name, middle initial, DOB, gender and race 
3) frrst name, last name, DOB, gender, and race 
4) frrst initial, middle initial, last name, DOB and state of residence 
5) fust name, New York State Identification and Intelligence System (NYSIIS)-
coded last name, DOB, state of residence, gender and race 
6) frrst name, last name, DOB +I- 1 year, state of residence, gender and race. 
1 The NDI provides files listing the top two hundred fifty most frequent last names in the United 
States in hoth alphabetical order and in order of decreasing frequency. 
Appendix C. The demographic, clinical and social variables reported by the 






Country of origin 
Clinical 
Major site ofTB infection 
Sputum smear results 
Sputum culture results 
Chest radiograph results 
HIV status 
Initial drug susceptibility results 
Social 
Excess alcohol use in preceding 12 months 
Homeless in preceding 12 months 
Resident oflong-term care facility at diagnosis 
Incarceration at time of diagnosis 
Injection drug use in preceding 12 months 
Non-injection drug use in preceding 12 months 
Table 1. Baseline characteristics of all TB patients captured by the NC TB Control 
Program from 1993-2003 N=5 311 
' 
Age 
<5 years old 2.1%(n= Ill) 
5-14 years old 2.3% (n = 121) 
15-24 years old 6.0% (n = 319) 
25-44 years old 30.4%(n = 1,614) 
45-64 years old 28.7% (n = 1,522) 
>65 years old 30.6% (n = 1,624) 
Gender 
Female 34.5% (n = 1,834) 
Race 
White 35.2% (n = 1,871) 
Black 58.9% (n = 3,128) 
Asian/Pacific Islander 5.8% (n = 308) 
American Indian/ Alaskan Native 0.8% (n=44) 
Ethnicity 
Hispanic 10.5% (n = 559) 
Country of Origin 
United States 81.9% (n = 4,348) 
Previous Diagnosis of TB 
Yes 5.6% (n = 296) 
Disease Site 
Pulmonary: 75.0% (n = 3,982) 
Pulmonary and Extrapulmonary: 4.6% (n = 243) 
Extrapulmonary Alone: 
Lymphatic 5.2% (n = 278) 
Miliary 2.2% (n = 119) 
Pleural 5.4% (n = 286) 
Bone/Joint 2.4% (n=l26) 
Other1 5.2% (n = 277) 
HIVStatus 
Positive 10.3% (n = 549) 
Negative 49.9% (n=2,650) 
Status Unkoown 39.7% (~ = 2,109) 
Resident of Corredional Facility at Time of TB Diagnosis 
Yes 2.0% (n = I 06) 
Resident of Long Term Care Facility at Time of TB Diagnosis 
Yes 4.7% (n = 250) 
Homeless Within Past Year 
Yes 7.1%(n=377) 
Injection Drug Use (IDU) Within Past Year 
Yes 1.8%(n=96) 
No 83.2% (n = 4,420) 
Unkoown 15.0%(n = 795). 
Non-injection Drug Use Within Past Year 
Yes 9.1% (n = 483) 
No 76.2% (n = 4,047) 
Unkoown 14.7% (n = 781) 
Excess Alcohol Use Within Past Year 
Yes 21.6% (n = 1,147) 
No 64.2% (n = 3,411) 
Unkoown 14.2%-(n = 753) 
"' 
,. Other mcludes menmgeal TB, gemtourmary TB, pentoneal TB and any other TB sttes 
Table 2. Disease-related characteristics 
Of pulmonary TB patients.* N- 4225 
Chest Radiograph Result 
Abnormal 97.0% (n = 4,099) 
Chest Radiograph Impression 
Cavitary 28.6% (n = 1,208) 
Radiograph suggestive ofTB, without cavitation 65.9% (n = 2,687) 
Radiograph not suggestive ofTB, without cavitation 4.5% (n = 185) 
Sputum Smear Result 
Positive 49.8% (n = 2,103) 
Negative 35.1% (n = 1,482) 
Sputum Smear Not Done 15.1%(n=636) 
Sputum Culture Result 
Positive 70.0% (n = 2,953) 
Negative 14.8% (n = 624) 
Sputum Culture Not Done 15.2% (n = 639) 
Of all patients. N - 5311 
Initial Organism Drug Susceptibility 
Resistant to INH alone 1.7% (n=90) 
Resistant to INH and to '-=:1 drug other than Rifampin 1.4% (n=76) 
Resistant to Rifampin and INH 0.4%(n=21) 
Resistant to Rifampin alone 0.2%(n= 10) 
Other Result 96.3% (n = 5114) 
*Includes those with both pulmonary and extrapulmonary TB disease. 
Table 3. Frequency ofTB death, at different times relative to treatment. 
'. 
. 
Time of Death No. Died/ No. Surviving Mortality 
! 
Up to the Specified Frequency 





Prior to initiation of treatment 181 I 5,311 3.41 
Early during treatment 305 I 5,130 5.95 
(InitialS weeks of treatment) 
Later during treatment 235 I 4,825 4.87 
(After the first 8 weeks of treatment) 
After treatment completion* 793 I 4,590 17.28 
* Deaths captured up until December 31, 2003 
Table 4. Demographic Characteristics of Study Patients, by Outcome Group. N = 5311 
Age (years) 
<5 0.0(0) 111(100) 0.9(1) 99.1(110) 0.0(0) 100(110) 
5-14 0.0(0) 121(100) 0.8(1) 99.2(120 0.00(0) 100(120) 
15-24 0.6(2) 99.4(317) 0.0(0) 100(317) 1.6(5) 98.4(312) 
25-44 1.8(29) 98.2(1585) 1.4(22) 98.6(1563) 2.4(37) 97.6(1526) 
45-64 3.2(48) 96.9(1474) 3.7(54) 96.3(1420) 3.6(51) 96.4(1369) 
141 
' 
Race 0.002 0.001 1 o.oo1 
White 3.3(61) 96.7(1811) 5.3(96) 94.7(1715) 4.4(75) 95.6(1640) 
Black 3.6(112) 96.4(2972) 6.7(200) 93.3(2772) 5.7(157) 94.3(2615) 
Asian/PI 1.0(3) 99.0(305) 1.6(5) 98.4(300) 0.7(2) 99.3(298) 
Amer. Indian 11.4(5) 88.6(39) 10.3(4) 89.7(35) 2.9(1) 97. 
Ethnicity 0.047 





Country of I I I <o.oo1 
Origin 
u.s. I 3.9(168) I 96.1(4180) I I 7.1(295) I 92.9(3885) I I 5.9(229) I 94.1(3656) 
1.2(11) 98.8(948) 1.1(10) 98.9(938) 0. 
, • ,,, ,, " ,_, '""'-~"''"''-~ ·-•·1'''-'"1 "I"' 





Extrapulmonary 3.8(41) 96.2(1045) 4.8(50) 95.2(995) I I 5.9(59) 
Pulmonary 3.4(134) 96.6(3848) 6.1(235) 93.9(3613) 
Both 2.5(6) 97.5(237) 8.4(20) 9 
Initial Drug 0.599 I 0.676 I I I 0.623 
Susceptibility 
Resist. to RIF alone 0.0(0) 100(10) 10.0(1) 90.0(9) 0.0(0) 100(9) 
Resist. to INH alone 1.1(1) 98.9(89) 7.9(7) 92.1(82) 7.3(6) 92.7(76) 
Resist. to RIF and 0.0(0) 100(21) 4.8(1) 95.2(20) 0.0(0) 100(20) 
INH 
Resist. to INH and I 2.6(2) I 97.4(74) I I 2.7(2) I 97.3(72) I I 4.2(3) I 95.8(69) 
?: 1 other drug 
Other Result 3 
HIVStatus <0.001 <0.001 1 <o.oo1 
Negative 0.9(24) 99.1(2626) 3.7(98) 96.3(2528) 2.3(59) 97.7(2469) 
Positive 4.6(25) 95.4(524) 4.0(21) 96.0(503) 9.7(49) 90.3(454) 
93.8(1978) 9.4(186) 90.6(1792) 7. 
*Based on diagnostic tests performed on pulmonary TB patients 
Table 6. 
Yes 2.4(9) 97.6(368) 4.9(18) 95.1(350) 3.1(11) 96.9(339) 
No 3.4(167) 96.6(4731) 6.0(282) 94.0(4449) 5.0(223) 95.0(4226) 
Unknown 13.9(5) 86.1(31) 16.1(5) 83.9(26) 3.8(1) 96.2(25) 
0.383 0.030 
Yes 1.9 (2) 98.1(104) 1.0(1) 99.0(103) 1.0(1) 99.0(102) 
No 3.4(179) 96.6(5026) 6.1(304) 93.9(4722) 5.0(234) 95.0(4488) 





8.8(22) 91.2(228) 21.5(49) 78.5(179) 15.1(27) 84.9(152) 
No 3.1(158) 96.9(4902) 5.2(256) 94.8(4646) 4.5(208) 95.5(4438) 
<0.001 0.442 I 0.024 
Yes 4.2(4) 95.8(92) 6.5(6) 93.5(86) 8.1(7) 91.9(79) 
No 2.6(116) 97.4(4304) 5.8(248) 94.2(4056) 4.5(183) 95.5(3873) 
Unknown 7.7(61) 92.3(734) 7.0(51) 93.0(683) 6.6(45) 93.4(638) 
<0.001 0.021 
Yes 1.5(7) 98.5(476) 3.4(16) 96.6(460) 4.8(22) 95.2(438) 
No 2.9(117) 97.1(3930) 6.0(237) 94.0(3693) 4.5(168) 95.5(3525) 
Unknown 7.3(57) 92.7(724) 7.2(52) 92.8(672) 6.7(45) 93.3(627) 
Excess Alcohol <0.001 0.303 I o.oo1 
Use' 
Yes 2.2(25) 97.8(1122) 5.3(1122) 94.7(1063) 3.2(34) 96.8(1029) 
No 3.0(101) 97.0(3310) 6.0(197) 94.0(3113) 5.0(155) 95.0(2958) 
Unknown 7.3(55) 92.7(698) 7.0(49) 93.0(649) 7.1(46) 92.9(603) 
Table 7. Mortality before initiation ofTB treatment; statistically significant 
results from multivariate logistic regression modeling. 
Age1 
Per year of life 
















Table 8. Mortality early in TB treatment and mortality later in TB treatment; 
significant results from extended Cox Proportional Hazards modeling. 
Age1 <0.001 <0.001 
Per year of life 1.06 1.05-l.o? 1.05 1.04-1.06 
Per decade of 1.79 1.63-1.97 1.63 1.48-1.79 
life 
Black race 1.35 1.05-1.75 0.021 ** ** ** 
HIV/TB co-
infection 






1.68 1.17-2.41 0.005 
1.70 1.23-2.34 0.001 
1 Analyzed as a continuous variable 
2 Within the previous 12 months 
3 At time of diagnosis 
**Not significant in the model 
** ** ** 
** ** ** 
Table 9. Mortality before and during TB treatment. Results of the multiple imputations• of the multivariate logistic regression modelb and the 
extended Cox Pro rtional Hazards models< to account for missin data. 
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1 Analyzed as a continuous variable 
1.03-1.05 <0.001 1.05 1.05-1.06 
2.16-5.77 <0.001 1.28 0.84-1.94 
** ** 1.34 1.04-1.72 
1.38-10.56 0.010 ** ** 
•• •• 1.48 1.02-2.15 
•• •• 1.68 1.21-2.32 
o Used in analysis of "Died Before Treatment" -= Used in 
'Within the previous 12 months 3 At time of diagnosis 
<0.001 1.05 1.04-1.06 
0.244 2.98 1.71-5.20 
0.025 ** ** 
•• ** •• 
0.039 •• ** 
0.002 •• •• 
s of"' Died Early in Treatment" and 
• • Not significant in the model 
<0.001 
<0.001 
** 
•• 
** 
•• 
in' 
